Structured PREreview of The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways Is a Means to an End

Does the introduction explain the objective of the research presented in the preprint?

Yes

The paper provides a comprehensive overview of precision oncology, focusing on the genetic and molecular profiling of tumors to tailor individualized cancer treatments, which is the main objective of the paper.

Are the methods well-suited for this research?

Highly appropriate

Because it is a review paper that synthesizes up-to-date literature on precision oncology and future treatment.

Are the conclusions supported by the data?

Somewhat supported

The conclusion highlights the transformative potential of precision oncology in delivering individualized, effective cancer care, reflecting the forward-looking tone and interdisciplinary scope of the review. However, it did not reiterate some of the tangible clinical impacts or ongoing challenges, such as disparities in access, cost implications, or the translational gap from genomic insights to approved therapies.

Are the data presentations, including visualizations, well-suited to represent the data?

Somewhat appropriate and clear

While Table 1, detailing representative cancer biomarkers and associated signaling pathways, and the accompanying figure of intracellular signaling networks offer a helpful visual overview of complex interactions, the manuscript largely consists of text-dense, highly technical sections. These cover numerous signaling cascades and targeted cancer therapies. Incorporating additional summary diagrams or mechanistic pathway maps would significantly improve clarity and enhance reader comprehension.

How clearly do the authors discuss, explain, and interpret their findings and potential next steps for the research?

Very clearly

The author articulates findings with exceptional clarity and insight, effectively bridging the molecular and genetic underpinnings of cancer progression with the technological innovations, therapeutic strategies, and clinical frameworks essential to advancing precision oncology. Although the manuscript does not introduce novel experimental data, it excels as a review by adeptly synthesizing complex concepts across diverse domains, including genomics, molecular biology, drug development, artificial intelligence, and cancer immunotherapy. The author also anticipates future directions by advocating for the integration of AI to enhance treatment personalization.

Is the preprint likely to advance academic knowledge?

Highly likely

The manuscript presents a sweeping, up-to-date synthesis of developments in molecular cancer therapeutics. Such comprehensive reviews serve as pivotal references in translational and molecular oncology, especially for early-career researchers, clinicians, and even AI developers interested in medical applications.

Would it benefit from language editing?

Yes

A professional editorial pass to correct minor typographic and grammatical issues could polish clarity and academic tone.

Would you recommend this preprint to others?

Yes, it’s of high quality

By integrating multi-disciplinary approaches, this review bridges basic science with translational medicine. It offers a panoramic view of how precision oncology is moving from theory to bedside application, making it a valuable resource for clinicians, researchers, and pharmacologists.

Is it ready for attention from an editor, publisher or broader audience?

Yes, after minor changes

Incorporating the issues raised in this review will improve the overall standard of the manuscript.

Competing interests

The authors declare that they have no competing interests.